Incyte Corporation
HealthcareNASDAQ:INCY · NASDAQ Global Select
+$0.70 today
Vol 1.47M · Avg 1.54M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
24.9%
avg 8.3%
ROIC
20.6%
avg 5.8%
ROA
18.5%
avg 5.0%
Analysis
ROE is currently the strongest return metric at 24.9% versus its period average of 8.3%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Mohamed Khairie Issa | Executive Vice President & Head of U.S. Commercial | $2.27M | — | 43 | $14,237.00 | <0.01% |
Pablo J. Cagnoni | President and Global Head of Research & Development | $2.07M | — | 63 | $266,317.00 | 0.13% |
William Meury | CEO & Director | $2.00M | — | 58 | $161,101.00 | 0.08% |
Steven H. Stein | Executive VP, Head of Late-stage Development & Chief Medical Officer | $1.57M | — | 59 | $78,327.00 | 0.04% |
Suketu Upadhyay | Executive Vice President & Chief Financial Officer | $1.40M | — | 57 | $38,429.00 | 0.02% |
Thomas Tray | Principal Financial Officer, Vice President of Finance & Chief Accounting Officer | $529,848.00 | — | 48 | $23,771.00 | 0.01% |
Patrick Mayes | Vice President of Biotherapeutic Research | — | — | — | $4,218.00 | <0.01% |
Xiaozhao Wang | Associate VP & Head of Medicinal Chemistry | — | — | — | — | — |
David Gardner | Executive VP & Chief Strategy Officer | — | — | 42 | $9,429.00 | <0.01% |
Lee J. Heeson | Executive VP & Head of Incyte International | — | — | 55 | $38,041.00 | 0.02% |
Michael James Morrissey | Executive Vice President & Head of Global Technical Operations | — | — | 62 | $34,065.00 | 0.02% |
Richard A. Hoffman | Executive VP & General Counsel | — | — | — | $43,301.00 | 0.02% |
Alexis Smith | Vice President & Head of Investor Relations | — | — | — | — | — |
Pamela Murphy | Vice President of Investor Relations & Corporate Communications | — | — | 75 | — | — |
James H. Lee | Group Vice President, Head of Inflammation & AutoImmunity Group | — | — | — | $34,065.00 | 0.02% |
Soni K. Basi | Executive Vice President & Chief Human Resources Officer | — | — | — | $16,265.00 | <0.01% |
Greg Shertzer | Senior Director of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
36
$40.98M
Net Sentiment
$40.98M
Net selling
Most Active
Denton Sheila A.
11 transactions
1–10 of 36
Analysis
Insiders reported 0 buys worth $0.00 and 36 sells worth $40.98M over the last 12 months. That adds up to net selling of $40.98M. Denton Sheila A. was the most active insider with 11 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +38.3% (15yr)5 analysts |
| Revenue | N/A | N/A | +36.4% | +12.8% (15yr)11 analysts |
| Net Income | N/A | N/A | N/A | +37.6% (15yr)11 analysts |
| EBIT | N/A | N/A | +253.4% | +21.1% (15yr)11 analysts |
Analysis
Recent growth has been strongest in EBIT at +253.4% over three years. Forward estimates point to EPS at +38.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Biogen Inc.
NASDAQ:BIIB
$29.53B
Illumina, Inc.
NASDAQ:ILMN
$24.35B
Royalty Pharma plc
NASDAQ:RPRX
$23.60B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.23B
Waters Corporation
NYSE:WAT
$23.17B
United Therapeutics Corporation
NASDAQ:UTHR
$23.17B
Quest Diagnostics Incorporated
NYSE:DGX
$22.48B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.13B
Genmab A/S
NASDAQ:GMAB
$15.40B
Tenet Healthcare Corporation
NYSE:THC
$15.04B
Who manages INCY?
Incyte Corporation (INCY) lists 17 active executives. The top listed executive is Pablo J. Cagnoni, President and Global Head of Research & Development.
Are INCY insiders buying or selling?
Recent insider activity shows net selling of $10.34M.
Explore More
Continue the stock analysis
Jump to another research area for this company.